Disease modification in osteoarthritis: are we there yet?

Disease modification in osteoarthritis: are we there yet? Clin Exp Rheumatol. 2019 Sep-Oct;37 Suppl 120(5):135-140 Authors: Oo WM, Hunter DJ Abstract A disease-modifying osteoarthritis drug (DMOAD) is a drug that modifies the underlying OA pathophysiology and potentially inhibits the structural damage to prevent or reduce long-term disability with potential symptomatic relief. The focus of this narrative review is on describing the state of the field for disease-modifying pharmacologic agents that are in late-stage development-specifically phase 2/3. PMID: 31621568 [PubMed - in process]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research